Processing

Please wait...

Settings

Settings

Goto Application

1. MXMX/a/2010/003762 - HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES

Office
Mexico
Application Number MX/a/2010/003762
Application Date 07.04.2010
Publication Number MX/a/2010/003762
Publication Date 27.10.2010
Publication Kind A
IPC
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Applicants TECHNOLOGIE INTÉGRALE LIMITED
Inventors ELENA YU FILINOVA
Agents MANUEL MARTIN SOTO GUTIERREZ
Priority Data 60/978,536 09.10.2007 US
Title
(EN) HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES
(ES) VACUNA PREVENTIVA CONTRA VIH A BASE DE ANTICUERPOS ESPECIFICOS CONTRA VIH
Abstract
(EN) The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response in an individual, which bind to existing in a current epidemiologic cohort HIV-subtypes and mutants selected after antiretroviral therapy. The present invention also relates to HIV-1 peptides/polypeptides/proteins selection with reverse panning technique, LC mass spectrometry identification of HIV-1 env peptides/polypeptides/proteins, gp120 and its fragment in particular, production of recombinant HIV-1 env peptides in suitable host with necessary glycosylation - L. tarentolae and using sterically stabilized liposomes (SSL) as an adjuvant-carrier for HIV-specific immune boost composition.
(ES) La presente invención se refiere a un método para producir una vacuna contra VIH, prevenir infección con VIH y/o prevenir el desarrollo de infección por VIH en un individuo. En particular, la presente invención proporciona la formación de anticuerpos específicos contra VIH capaces de reconocer y unirse sustancialmente a todas las isoformas de VIH cono una respuesta inmunitaria en un individuo, los cuales se unen a subtipos de VIH de cohortes epidemiológicos que existen en una corriente y mutantes seleccionados después de terapia antirretroviral. La presente invención también se refiere a selección de péptidos/polipéptidos/proteínas de VIH-1 con técnica de tamizado inverso, identificación por espectrometría de masas LC de péptidos/polipéptidos/proteínas env de VIH-1, gp120 y su fragmento en particular, producción de péptidos env de VIH-1 recombinantes en hospederos adecuados con glicosilación necesaria - L. tarentolae y usando liposomas estericamente estabilizados (SSL) como un adyuvante-portador para una composición de refuerzo inmunitario especifica contra VIH.
Related patent documents
RU2010116849This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.